Single-cell sequencing profiling of intratumoral heterogeneity and immunosuppressive microenvironment in primary thyroid cancer and lymph node metastases.
Thyroid cancer uses a different immune-evasion tactic than previously thought, pointing toward new immunotherapy targets.
Single-cell transcriptomic atlas of primary thyroid cancer and lymph node metastases reveals that LAG3-LGALS3 signaling, rather than canonical PD-1/PD-L1 pathways, dominates the immune evasion landscape in the thyroid cancer metastatic niche. Enrichment of FOXP3+ regulatory T cells, LAMP3+ dendritic cells, and CCL18+ M2-like macrophages further defines targetable axes for immunotherapy trials in thyroid cancer.
What the study was
- Study design
- single-cell transcriptomic atlas study
- Population
- Primary thyroid cancer and lymph node metastasis patients
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Oncoimmunology
Why it surfaced
Identifies LAG3/TIGIT as alternative checkpoint targets in thyroid cancer via comprehensive scRNA atlas; challenges conventional PD-1 approach; actionable for immunotherapy trial design in thyroid cancer.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.